StemCell Therapy

ReportLinker

The Global Type 2 Diabetes Drugs Market size was estimated at USD 60. 82 billion in 2021 and expected to reach USD 65. 75 billion in 2022, and is projected to grow at a CAGR 8. 38% to reach USD 98.

New York, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Type 2 Diabetes Drugs Market Research Report by Drug, Application, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06342114/?utm_source=GNW 62 billion by 2027.

Market Statistics:The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:This research report categorizes the Type 2 Diabetes Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug, the market was studied across Injectables and Oral. The Injectables is further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral is further studied across Alpha-Glucosidase Inhibitors, Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide, Receptor Agonists, Secretagogues, Sodium Glucose Cotransport 2 Inhibitors, Sulfonylureas, and Thiazolidinediones.

Based on Application, the market was studied across Cardiovascular Safety, Glycemic Control, and Hypoglycemia Avoidance.

Based on Distribution, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Type 2 Diabetes Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Type 2 Diabetes Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitors strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Type 2 Diabetes Drugs Market, including Abbott Laboratories, Amgen Inc., AstraZeneca Plc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Daiichi Sankyo Co. Ltd, Eli Lilly and Co., GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk AS, Peptron, Pfizer Inc., Sanofi Aventis A/S, Sanofi SA, Sun Pharmaceutical Industries Limited, and Takeda Pharmaceutical Co. Ltd.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Type 2 Diabetes Drugs Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 2 Diabetes Drugs Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 2 Diabetes Drugs Market?4. What is the competitive strategic window for opportunities in the Global Type 2 Diabetes Drugs Market?5. What are the technology trends and regulatory frameworks in the Global Type 2 Diabetes Drugs Market?6. What is the market share of the leading vendors in the Global Type 2 Diabetes Drugs Market?7. What modes and strategic moves are considered suitable for entering the Global Type 2 Diabetes Drugs Market?Read the full report: https://www.reportlinker.com/p06342114/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

More:
Type 2 Diabetes Drugs Market Research Report by Drug, Application, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 -...

Diabetes causes a persons blood sugar levels to become too high, which must be handled carefully to prevent further complications. Unfortunately, the condition doesn't always produce obvious symptoms. Excessive sweating at night, however, could be a sign that high blood sugar has damaged the nerves.

Excessive can both be a sign of low blood sugar levels and blood sugar damage to nerves.

The most common reason for unusual sweating in people with the condition, however, is diabetes-related nervous system damage.

According to the American Diabetes Association, approximately half of people with diabetes experience some level of nerve damage.

When nerve damage occurs, known as autonomic neuropathy, it occasionally affects the sweat glands.

READ MORE:Diabetes: Summer foods that could spike blood sugar

High blood sugar and high levels of fat, such as triglycerides, can damage the nerves or the blood vessels that nourish the nerves.

This may produce several different symptoms depending on which of the bodys functions are affected.

The National Institute of Diabetes and Digestive and Kidney Diseases says: Damage to the nerves that control your sweat glands may cause you to sweat a lot at night or while eating.

Your sweat glands may not work at all, or certain parts of your body may sweat while other parts are dry.

DON'T MISS:

If your sweat glands do not work properly, your body may not be able to control its temperature.

Sometimes nerve damage prevents signals from being sent to different parts of the body, which can result in numbness.

Other types of discomfort may occur, such as sharp pains, cramps, muscle weakness or sensitivity to touch.

Depending on the nerves affected, neuropathy can cause these sensations in the hands, feet, and legs.

READ MORE:Diabetes warning: Do not 'overindulge' in a particular type of fruit

The Centers for Disease Control and Prevention says: Nerve damage can cause health problems ranging from mild numbness to pain that makes it hard to do normal activities."

There are several steps that can help prevent diabetes, but the most logical starting point is diet.

It is advisable to choose whole grain products over refined grained ones and other highly processed carbohydrates.

This is because refined carbohydrates can increase blood triglycerides, and blood sugar levels and cause insulin resistance, which are major risk factors for diabetes.

There are also many benefits to regular physical activity for blood sugar control, as it can help keep them within a healthy range for up to 48 hours.

Plants, which provide a wealth of vitamins, minerals and carbohydrates, are good energy sources for the body.

Dietary fibre can also slow the absorption of sugars and interfere with the absorption of dietary cholesterol.

These food sources also promote weight loss, which in turn may lower the risk of diabetes.

See the rest here:
Diabetes symptoms: The sign of nerve damage that often strikes at night - severe - Express

What is Diabetes?

Diabetes is the seventh-leading cause of death in the United States.

Diabetes is a long-lasting health condition that affects how your body turns food into energy. With diabetes, your body either doesnt make enough insulin or cant use it as well as it should.

Most of the food you eat is broken down into sugar (also called glucose) and released into your bloodstream. When your blood sugar goes up, it signals your pancreas to release insulin. Insulin acts like a key to let the blood sugar into your bodys cells for use as energy.

If you have diabetes, your body either doesnt make enough insulin or cant use the insulin it makes as well as it should. When there isnt enough insulin or cells stop responding to insulin, too much blood sugar stays in your bloodstream.

Over time, that can cause serious health problems, such as heart disease, vision loss, and kidney disease.

Types & symptoms

Type 1 diabetes is thought to be caused by an autoimmune reaction (the body attacks itself by mistake) that stops your body from making insulin. Approximately 5-10% of the people who have diabetes have type 1.

Symptoms of type 1 diabetes often develop quickly. Its usually diagnosed in children, teens, and young adults. Currently, no one knows how to prevent type 1 diabetes.

People who have type 1 diabetes may also have nausea, vomiting, or stomach pains. Type 1 diabetes symptoms can develop in just a few weeks or months and can be severe.

Type 2 diabetes occurs when your body doesnt use insulin well and cant keep blood sugar at normal levels. About 90-95% of people with diabetes have type 2. It develops over many years and is usually diagnosed in adults; however more children, teens, and young adults are developing type 2 diabetes.

With healthy lifestyle changes, such as eating healthy food, losing weight, and being active Type 2 diabetes can be prevented or delayed.

Some people dont notice any symptoms at all. Because symptoms are hard to spot, its important to know the risk factors for type 2 diabetes. Make sure to visit your doctor if you have any of them.

Gestational diabetes develops in pregnant women who have never had diabetes. If you have gestational diabetes, your baby could be at higher risk for health problems.

Gestational diabetes usually goes away after your baby is born but increases your risk for type 2 diabetes later in life. Your baby is more likely to develop type 2 diabetes later in life too. Gestational diabetes (diabetes during pregnancy) usually doesnt have any symptoms.

If youre pregnant, your doctor will test you for gestational diabetes between 24 and 28 weeks of pregnancy.

Symptoms & risk factors

Diabetes symptoms may include an increase in thirst, urinating a lot, lose of weight without trying, increased hunger, blurry vision, dry skin, feeling tired, numbness or tingling in your hands or feet, sores or wounds that heal slowly. If you have any of the following diabetes symptoms, see your doctor.

Risk factors for developing type 2 diabetes can include a history of prediabetes, being over the age of 45, overweight, having a parent or sibling with type 2 diabetes, or ever had gestational diabetes, are physically active less than 3 times a week.

There isnt a cure yet for diabetes, but losing weight, eating healthy food, and being active can help. Knowing diabetes risk factors and taking medicine as directed, you can prevent or delay type 2 diabetes with lifestyle changes.

Diabetes self-management education, support, and keeping your health care appointments can reduce the impact of diabetes on your Life! Please see the American Diabetes Association https://www.diabetes.org/, for further information .

Source: Centers for Disease Control Prevention.

Michaella Quallen is with the Clinton County Health District.

Read the rest here:
Diabetes: Symptoms, risks, and prevention - Wilmington News Journal, OH

Alexandra drops TD1 kits off to a Yonkers school (Photo by Jason Malkin)

An Ardsley teen is working to make life with type 1 diabetes easier on local kids. Alexandra Malkin, a rising senior at Ardsley High School, started T1D Kits for Kids to provide free essential health supplies (along with a few small treats) to elementary-aged children. And people are taking notice she was recently named Hero of the Day by Good Day New York for her work.

Malkin saw firsthand what kind of hardships kids face with juvenile diabetes after her childhood friend was diagnosed with the condition at age 9. As I watched her life change extremely quickly, I began to understand the true impact that diabetes can have on someones life especially at a very young age, she told River Journal.

The experience stayed with her. Malkin decided to focus on diabetes once she was accepted into her schools science research program, a 3-year elective that allows students to dive into specific research areas. After reading various articles on past diabetic studies during the year, I was sure I wanted it to be what I would study for the remainder of my time in the program influencing the two summer research projects I have been a part of involving diabetes.

While immersing herself in the science, Malkin also discovered that the high costs associated with type 1 diabetes can be especially detrimental to children. More recently, I found out from a friend that their cousin who works at an elementary school in Michigan has seen a lot of diabetic students who arent able to afford the basic diabetic technology, she said. As I looked into this issue more, I noticed extremely high prices of diabetic kits sold by large diabetes companies more than any underprivileged family could afford.

This sparked the idea to provide children with the devices and medical supplies needed for free. Her kits include glucose monitors, lancets, Band-Aids, batteries, and glucose tabs, basic and necessary tools to stay healthy throughout the day. While those items will make many parents happy, Malkin doesnt forget her main focus: kids with juvenile diabetes. She tucks a few treats inside each basket to make them smile. I also wanted to address the desire for comfort from young type-1 diabetics by including teddy bears, sugar-free candy, and bracelets, pins, that help them embrace their T1D identity.

Since kicking off in January, Malkin has donated batches of kits to three different elementary schools, where she works with nurses to identify those who would benefit from them most. The greatest amount of newly-diagnosed type 1 diabetics usually are found within that age group (kindergarten 4th grade), she noted. The kits have been specialized to appeal to this

age group as well. Shes working to keep relationships with the schools, and has been sent photos of the recipients holding the kits and smiling ear-to-ear.

Malkin hopes to expand the program outside Westchester in the future and has applied for grants to continue funding and upgrading her kits. And she wants to help connect children with juvenile diabetes through their stories. I also have an idea to create a diabetes advice book that would include advice from experienced type 1 diabetics to help the younger diabetics make a smoother transition and feel like they arent alone.

To help keep the program going, Malkin said sharing her work with others and making a donation would go a long way. The only way to truly make my organization grow is to promote necessary funding and recognition for the work of T1D Kits for Kids and the concept behind it, she said. With these contributions, I can achieve the goals I have for the non-profit and expand my impact to the larger diabetic community.

Visit t1dkitsforkids.org to learn more or to make a donation.

Read more:
Local Teen Brings Smiles and Health Kits to Kids with Diabetes - River Journal Staff

While most of us are familiar with type 1 and type 2 diabetes, you may not have come across the term type 3 diabetes before. First things first, this is not to be confused with type 3c diabetes, which is something else entirely. It is, however, related to insulin resistance in the brain.

Being diagnosed as insulin resistant generally means that someone is either prebiabetic or has type 2 diabetes. But scientists have proposed that it can also result in the brains neurons lacking glucose, which is needed for proper function, and this can lead to symptoms of Alzheimer's disease.

While type 3 diabetes is not an officially recognised health condition, in 2008 Dr Suzanne de la Monte and Dr Jack Wands of Brown University put forward a proposal that Alzheimers disease could be termed type 3 diabetes due to its strong links with insulin resistance. Insulin resistance may be a leading cause of dementia, as this glucose deficiency in the brain leads to symptoms such as loss of memory, decrease in judgment and reasoning skills.

Type 3 diabetes is not a medically recognised term and is not something doctors use for diagnostic purposes. However, insulin resistance and decreased insulin signaling in the brain may play a role in the development of Alzheimer's disease. Not to mention, the risk of developing Alzheimer's disease is significantly higher in those with type 2 diabetes. As such, the term type 3 diabetes has been colloquially used by some in the field to illustrate these links.

A study in the Lancet journal of Neurology (opens in new tab) links diabetes with declining brain health and indicates that treatments that restore cerebral insulin function may offer therapeutic benefits to those with Alzheimer's disease.

Dr. William H Frey II, an Alzheimer's specialist at the Health Partners Center for Memory and Aging (opens in new tab), also explains that the disease causes cognitive decline in patients. Alzheimer's is a degenerative brain disease that accounts for more than 60% of the cases of dementia, he tells Live Science. It is characterized by memory loss, especially short-term or recent memories, cognitive decline and changes in behavior, all of which get progressively worse over time.

Dr Tariq Mahmood, a doctor and medical director at Concepto Diagnostics (opens in new tab), adds: Type 3 diabetes isnt an officially recognised health condition and isnt used for diagnostic purposes. It differs from type 1 diabetes and type 2 diabetes, which cause blood sugar levels to become too high due to issues with a hormone called insulin. Some scientists hypothesize that insulin dysregulation in the brain causes dementia and use type 3 diabetes as a term to describe Alzheimers disease a progressive neurological condition which is the most common cause of dementia.

Mahmood explains that while type 3 diabetes is not an official diagnosis, doctors can diagnose Alzheimers disease, which affects multiple brain functions gradually over the course of many years. Minor memory problems are usually the first sign, he says. More specific symptoms can include confusion, difficulty planning, disorientation, getting lost and personality changes.

Early to moderate symptoms of Alzeimers include:

These symptoms usually develop to a point that patients cannot swallow, lose bowel control and eventually pass away. Often people with Alzeimers die from aspiration pneumonia. This develops when food or liquids pass into the lungs instead of air due to problems with swallowing, as is stated by the National Institute of Aging (opens in new tab).

Dr Frey tells us that Alzheimers is best diagnosed by a neurologist who is familiar with neurodegenerative memory disorders. Diagnostic procedures may involve taking a complete history, blood tests, brain imaging, neuropsychological testing, etc. to help rule out other disorders that may produce somewhat similar symptoms, he says.

A review on insulin resistance in the Frontiers in Neuroscience (opens in new tab) journal indicates that insulin links multiple conditions together, such as obesity, dementia and diabetes, and recommends the potential use of antidiabetic medication to treat dementia. Additionally, the review explores the link between dementia and a high allostatic load, which is the burden created by stress, life events and other environmental challenges.

Mahmood tells us that while the science is unclear on the specific cause of Alzeimers disease, a combination of factors may be at play. Its widely believed that age-related neurological changes combined with genetic, environmental, and lifestyle factors can contribute toward it, he says. Age is the most important known risk factor for Alzheimers disease due to, among other things, atrophy in parts of the brain. Atrophy is the wasting of a muscle, meaning it can shrink, thin or be outright lost.

But Dr Frey explains that general aging is not the only risk factor associated with the development of Alziemers disease. Aging is the major risk factor for Alzheimer's disease, but Alzheimer's is not a normal part of aging, he says. Family history of Alzheimer's and genetic changes can also increase the risk, but individuals without a family history of the disease can still get Alzheimer's disease. A history of moderate traumatic brain injury can also significantly increase the risk for developing Alzheimer's disease.

Finally, type 2 diabetes doubles the risk for developing Alzheimer's disease. This is likely due to the fact that in both diabetes and Alzheimer's disease, there is a deficiency of insulin signaling.

He goes on to explain that In Alzheimer's disease, this insulin signaling deficiency occurs in the brain and leads to a loss of brain cell energy. Without sufficient insulin signaling, blood sugar is not taken into brain cells and metabolized normally.

Loss of brain cell energy means that the brain can no longer carry out memory and cognitive functions normally and also can not produce the parts of brain cells needed to replace those that wear out over time leading to degeneration of the brain itself.

Unhealthy lifestyles, including lack of exercise, poor diet and lack of sleep, likely also increase the risk for Alzheimer's disease, he says.

Dr Freys research has been pioneering in the area of insulin resistance and Alzheimer's. In 2022, he released a study in the Pharmaceuticals (opens in new tab) journal indicating that intranasal insulin (insulin administered up the nose) can help with cerebral glucose hypometabolism, which is a characteristic that is commonly found in those with degenerative cognitive disorders, as well as type 2 diabetes.

Because insufficient insulin signaling contributes to loss of brain cell energy in individuals with Alzheimer's disease, [we] first proposed intranasal insulin as a treatment for Alzheimer's disease about 22 years ago, he says. Intranasal insulin delivers and targets insulin to the brain along the nerves involved in smell without altering the blood levels of insulin or blood sugar.

But while clinical trials have shown that non-invasive intranasal insulin increases brain cell energy and improves memory in normal healthy adults, as well as those with mild cognitive impairment or Alzheimer's disease, it needs further development and testing to sufficiently demonstrate its safety and efficacy before it can be considered for regulatory approval and made available.

Dr Mahmood tells us that while there is regrettably no cure for Alzheimer's disease, treatments for those with the condition are available. There are medicines and treatments that can reduce symptoms on a temporary basis, he says. The two main medicines right now are acetylcholinesterase (AChE) inhibitors, which help nerve cells communicate with each other, and memantine, which blocks the effects of excessive glutamate this is a neurotransmitter released by nerve cells which plays a major role in learning and memory.

For people who begin to show aggression or distress, antipsychotic medicines can also be prescribed. For treatments, cognitive rehabilitation and cognitive stimulation therapy can help maintain memory and problem-solving skills.

A review in the Journal of Alzheimer's Disease (opens in new tab) indicates meditation may help with the prevention of Alzheimers disease, as it reduces allostatic load, which has been linked to the development of several cognitive disorders. Just 12 minutes of Kirtan Kriya meditation per day was shown to improve sleep, decrease depression, reduce anxiety, down regulate inflammatory genes, upregulate immune system genes, and improve insulin and glucose regulatory genes.

Dr Mahmood tells us that general healthy living is recommended to reduce your risk too, although other risk factors are uncontrollable. Unfortunately, theres no way to prevent Alzheimers disease at the moment, he says. Living a healthy lifestyle might lessen your risk, but age-related neurological changes and genetic factors are impossible to work around. Cardiovascular disease has been linked with an increased risk of Alzheimer's disease, so eating a balanced diet, making sure you get 150 minutes of exercise per week, limiting alcohol consumption and stopping smoking are all worthwhile.

Our easy Mediterranean diet plan and 7-day plant-based diet meal plan have lots of ideas to help you to eat a more balanced diet.

Dr Frey agrees that general healthy living is a wise course of action in working to avoid Alzheimer's disease. He also recommends protecting your head. Maintaining a healthy lifestyle including regular physical activity, avoiding head injury by wearing your seatbelt while in vehicles and a helmet during sports, consuming a healthy diet and remaining socially active can all help to reduce your risk for Alzheimer's disease, he says.

This article is for informational purposes only and is not meant to offer medical advice.

Original post:
Type 3 diabetes: symptoms, causes and treatments - Livescience.com

When you are traveling by vehicle to your destination, you should:

Once you reach your destination:

One of the most important aspects of managing Type 2 diabetes is for the patient to test their blood glucose level, usually twice a day. This could be more for some patients, depending on the care plan from their physician.

In an article in Healthline, Lisa Harris, CDE, RN at Rush University Medical Center in Chicago said that many patients with type 2 diabetes would likely benefit from testing more frequently. "Testing your blood sugar can be extremely informative for people when they're trying to prevent the need for further medication, like insulin," Harris said. "Even if they're only taking metformin, seeing for themselves how certain types of foods affect their blood sugar can have the biggest impact on motivating them to make changes in their diet."

In addition, when traveling, healthy eating tends to become more difficult to regularly sustain. People will usually eat out more and have less time to plan healthy meals or have fewer healthy options from which to choose. There's also less time to ensure proper nutrition and exercise which is important for managing diabetes.

"For people with diabetes, having their blood glucose readings sent to a provider is even more important when they travel because their diet might not be as healthy, eating times and patterns may shift, and other metabolic stressors related to traveling," said Dr. Bill Lewis, a leading telehealth consultant. "The iGlucose is the perfect traveling companion for people with diabetes so their test results are still being transmitted seamlessly to their provider."

Many of today's devices for at-home remote patient monitoring (RPM) rely on Bluetooth technology or Wi-fi paired to an app on a smartphone. These connections especially low-energy Bluetooth, can fail and may not reliably or securely deliver health data to providers.

The iGlucose from Smart Meter has proprietary cellular technology that utilizes the fast and secure 4/5G AT&T IoT network for reliable transmissions every time. With the cellular-enabled iGlucose, the measurement is sent immediately to the patient's provider with no extra steps required by the patient.

About Smart Meter, LLC

Now serving more than 100,000 patients, Smart Meter is the leading supplier of cellular-enabled virtual care technologies that include the iGlucose, iBloodPressure, iPulseOx, iScale, and SmartRPMcloud platform, as well as data, and services. Smart Meter's remote patient monitoring solutions are recognized as the standard for the RPM industry and are regarded for their high patient retention and satisfaction. The unique combination of reliable health data, patient-friendly devices, and platform integrations enable and enhance RPM, CCM, Employee Wellness, Population Health, and Telehealth programs for more than 300 RPM distribution partners across the United States. For more information, visitSmartMeterRPM.com

Smart Meter, LLC

Media Contact

5501 W. Waters Ave., Suite 401

Keith Tolbert

Tampa, FL 33602

[emailprotected]

813-773-4080

336-509-8024

SOURCE Smart Meter, LLC

The rest is here:
Diabetes Travel Essentials and Tips for the Approximately 21 Million Americans that Must Manage Their Diabetes While on Vacation - PR Newswire

News Release

Thursday, July 14, 2022

NIH-funded clinical trial finds that starting with a cheaper drug and switching to a more expensive drug as needed leads to good vision outcomes in diabetic macular edema.

Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug. The main complication of diabetic macular edema, fluid build-up in the retina that causes vision loss, is commonly treated with anti-vascular endothelial growth factor (VEGF) drugs.

The trial was funded by the National Eye Institute (NEI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both part of National Institutes of Health. Results of the trial, which examined a stepped regimen of anti-VEFG drugs Avastin (bevacizumab) and Eylea (aflibercept), were published today in the New England Journal of Medicine.

Our study showed that switching treatments when needed is a reasonable strategy, said Chirag Jhaveri, M.D., Austin Research Center for Retina, Texas, the lead study author. Insurance companies often require clinicians to start with the less expensive treatment, so we really wanted to see how a specific treatment strategy using this approach would affect patient care.

Diabetic macular edema is caused by diabetes-related alterations to retinal blood vessels. Symptoms include blurred vision. If untreated, vision loss can become permanent and progress to blindness. Retinal injections of anti-VEGF drugs can restore vision. The DRCR Retina Network previously showed that Avastin and Eylea improve visual acuity in people with diabetic macular edema. However, while Eylea is approved by the U.S. Food and Drug Administration to treat diabetic macular edema and results in better visual outcomes on average, off-label Avastin is much less expensive and is sometimes required by insurers as a first-line treatment.

The study enrolled 270 participants with diabetic macular edema, some of whom received treatments in both eyes. At enrollment, all had best-corrected visual acuity between 20/50 and 20/320. Half the study eyes were assigned to Eylea from the start, and half were assigned to start with Avastin. For participants who needed treatment in both eyes, each eye started treatment with a different drug. Participants received either Avastin or Eylea injections every four weeks for 24 weeks. If eyes assigned Avastin failed to reach the pre-set improvement benchmarks starting at 12 weeks, the eye was switched to Eylea.

After 24 weeks, physicians could taper down the frequency of injections as appropriate to maintain visual acuity. The study collected information about participants retinal structure and visual acuity for two years.

After two years, eyes in both groups had similar visual acuity outcomes, improving on average approximately three lines on an eye chart, compared to the trials start. In the Avastin group, 70% of eyes switched to Eylea during the study.

While most participants on Avastin eventually switched to Eylea, they still had improvement during those initial weeks, even if they didnt hit our pre-set benchmarks, said Adam Glassman of the Jaeb Center for Health Research and director of the DRCR Retina Network coordinating center. There are large cost disparities between these drugs, so differences in treatment strategies may have substantial cost implications.

Weve demonstrated here one method to managing a step treatment, where the outcomes are similar to the best existing treatment protocol with Eylea, said Jennifer Sun, M.D., M.P.H., of Joslin Diabetes Center and Harvard Medical School, Boston, and chair of diabetes initiatives for the DRCR Retina Network. Any time we can add to a clinicians toolbox, whether its a new medication or a new approach to using existing medications, as in this study, its a benefit for patients.

The study was supported by NEI (EY014231) and NIDDK through the Special Diabetes Program for Type 1 Diabetes Research. Clinical trial number NCT03321513.

NEI leads the federal governments research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Jhaveri CD, Glassman AR, Ferris FL, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK, DRCR Retina Network. Aflibercept monotherapy versus bevacizumab first followed by aflibercept if needed for treatment of center-involved diabetic macular edema. NEJM. July 14, 2022.

###

Continued here:
A type of 'step therapy' is an effective strategy for diabetic eye disease - National Institutes of Health (.gov)

International Diabetes Federation (IDF) reports one in five Google searches for terms related to diabetes reveal inaccurate information about the condition and how to manage its complications, showing the lack of reliable diabetes education available for those who have or may have the condition.

The number of people living with diabetes continues to rise around the world, with the latest IDF estimatesindicating that one in nine adults will be affected by 2030. The necessity for reliable, accessible and accurate data on the condition can be a matter of life or death for people with serious cases of diabetes.

When diabetes is undetected and inadequately treated especially treated through home remedies which are reliant on misinformed articles on diabetes education people with diabetes are at higher risk of serious and life-threatening complications.

This is putting added strain on healthcare systems that, following two years of a global pandemic, are already struggling.

Out of 30 search results (the first results page for each search term), six links directed users to unverified information for different diabetes terms.

Terms including diabetes, how to manage diabetes and diabetes symptoms featured results and answers to questions from non-medical sources including Wikipedia, Amazon and Facty the last of which showed an article on home remedies for diabetes.

In one case, when searching for the term diabetes, users were shown an advert from an organisation that aims to wean people living with diabetes from insulin this can be extremely dangerous for those with type 1 diabetes, because if they experience an interruption in their supply of insulin, it can be potentially fatal.

Researchers of this data strongly advocate that decisions to reduce insulin treatment should be taken in close consultation with a qualified healthcare professional, preferably a specialist in diabetes.

According to IDF figures, an estimated 44.7% of adults living with diabetes (240 million people) across the world are undiagnosed with the overwhelming majority having type 2 diabetes.

Professor Andrew Boulton, IDF President, says: Many people now turn to Google and the internet for advice, so its worrying that misinformation about diabetes is still rife online.

With the prevalence of diabetes showing no signs of declining, ensuring that healthcare professionals are equipped to provide the best possible care and that people with diabetes can make informed decisions about their self-care is more important than ever. We need quality education today to help protect tomorrow.

IDF is committed to facilitating learning opportunities for all people concerned by diabetes, so their newonline platformhas been launched providing free interactive courses to help people with diabetes and their carers to understand and manage their condition.

The first course available provides an introduction to diabetes, explaining what it is, how it works and the common warning signs and risk factors.

For healthcare professionals, theIDF School of Diabetesoffers a selection of free and premium online courses that help them to keep up-to-date with various aspects of diabetes education, management and treatment.

Editor's Recommended Articles

Read more:
Diabetes education: one in five search results for diabetes lack reliable information - Open Access Government

Since 2005, talented performers ages 8-18 from across the St. Louis region come together every summer to form the Arch City Kids Theater Troupe (ACTT), producing a Broadway-style musical revue to raise money and awareness for JDRF (formerly the Juvenile Diabetes Research Foundation) in hopes of finding a cure for Type 1 diabetes.

As always, this year's production, Don't Stop Believin', is run entirely by kids, who cast, direct, choreograph and perform the show, donating all proceeds to JDRF. Don't Stop Believin' is directed this year by 18-year-old 2022 Lutheran South graduate, Gracie Maurer.

"ACTT is my favorite part of the summer," she says. "I've met lifelong friends and grown as a leader. I'm so excited to be directing the show this year!"

In 2021, ACTT's production Something About This Night raised $25,000, and over the years, with participation of more than 200 area kids, ACTT has given nearly $300,000 to JDRF.

Being a part of ACTT has become a fun and meaningful summer tradition for many young St. Louis performers, but for Assistant Director Natalie McAtee, singing and dancing in the show is only part of the appeal.

"Being able to raise money doing what I love for a disease that affects my friends is the highlight of my summer," said Natalie.

Gracie agrees.

"I am looking forward to raising money to turn Type 1 into Type None."

Don't Stop Believin', featuring songs from Broadway favorites like Rock of Ages, Hairspray, Legally Blonde, A Chorus Line, and Mamma Mia, runs August 5-7 at Ladue Horton Watkins High School. Tickets are free but donations are encouraged. Raffles and concessions are available at each show, and all proceeds go to JDRF.

For more information on ACTT: https://cloud.broadwayworld.com/rec/ticketclick.cfm?fromlink=2186141id=81&articlelink=http%3A%2F%2Fwww.archcitykids.org%2F?utm_source=BWW2022&utm_medium=referral&utm_campaign=article&utm_content=bottombuybutton1

Read more from the original source:
Arch City Kids Theater Troupe Fights Type 1 Diabetes With Its Annual Revue - Broadway World

DUBLIN--(BUSINESS WIRE)--The "Nutrigenomics Testing Market - Growth, Trends, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

The Global Nutrigenomics Testing market is expected to register a 13.3% of CAGR over the forecast period. The major factors for the market growth are increasing burden of lifestyle disorders and gaining popularity of personalized diet. Some of the lifestyle diseases include heart disease, and stroke, obesity and diabetes.

According to the World Health organization, cardiovascular diseases are one of the leading causes of death and around three-quarter of the deaths occur in low- and middle-income countries. Moreover, diet plays an influential role on the health with respect to the prevention of diseases and the overall quality of life. Thus, the nutrigenomics testing market growth is expected to propel.

Key Market Trends

Obesity Segment Expected to Exhibit Significant Market Growth

According to the factsheet of National Health Service, as of May 2020, about 20% of the children aged 6 years were obese in the United Kingdom. Childhood obesity is often associated with higher risk of premature death, disability in adulthood, and other risks such as difficulty in breathing, increased risk of fractures, hypertension, early markers of cardiovascular disease, insulin resistance and psychological effects.

Furthermore, obesity has been a major issue in high-income countries, however in recent years it has seen an upsurge in low- and middle-income countries. In 2018, approximately 40 million children that were under the age of five were obese worldwide, nearly half of this population was found to in Asia. Thus, the rising burden of obesity is expected to have a positive impact on the nutrigenomics testing market.

North America Expected to Hold a Significant Share in the Market

North America is expected to be a dominant region in the Nutrigenomics Testing market owing to rising burden of diseases due to sedentary lifestyle adoption. According to the Centre for Disease Control and Prevention, in 2017-18, the prevalence of obesity in the United States was found to be around 42.4% in adults. The prevalence of obesity was found to be more in women as compared to men. Furthermore, as per the data of Diabetes Research Institute, 2018, 34.2 million people in the United States had diabetes. Hence, a personalised dietary approach is gaining popularity for prevention and treatment of such diseases. Therefore, the aforementioned factors are expected to rise the demand for nutrigenomics testing market growth.

Competitive Landscape

Companies are taking initiatives to grow their presence in the market. In 2019, PT Kalbe Farma Tbk. launched Nutrigen-me panel that includes hormones, methylation, inflammation and antioxidants, plus sleep and lifestyle. Key players that are expected to be dominant in Nutrigenomics Testing market are Orig3n, DNA Life, Genus Health, LLC, Sanger Genomics Pvt. Ltd., The Gene Box, GX Sciences,Inc., Nutrigenomix, Cura Integrative Medicine and Holistic Health

Key Topics Covered

1 INTRODUCTION 1.1 Study Assumptions1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview4.2 Market Drivers4.2.1 Increasing Prevalence of Lifestyle Disorders4.2.2 Increasing Popularity for Personalized Diet4.3 Market Restraints4.3.1 Stringent Regulatory Framework4.4 Porter's Five Force Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Application5.1.1 Obesity5.1.2 Diabetes5.1.3 Cancer5.1.4 Cardiovascular Disease5.2 Geography5.2.1 North America5.2.2 Europe5.2.3 Asia-Pacific5.2.4 Rest of the World

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles6.1.1 Cura Integrative Medicine6.1.2 DNA Life6.1.3 Genus Health, LLC6.1.4 GX Sciences, Inc.6.1.5 Holistic Health6.1.6 Nutrigenomix6.1.7 Orig3n6.1.8 Sanger Genomics Pvt. Ltd.6.1.9 The Gene Box

For more information about this report visit https://www.researchandmarkets.com/r/gp59f9

See the original post here:
Nutrigenomics Testing Industry Forecast to 2027 - Insights Into Obesity, Diabetes, Cancer, and Cardiovascular Disease Applications -...

Researchers have recently successfully treated Type 1 diabetes by transplanting insulin-producing pancreas cells into the patient.

University of Missouri scientists are partnering with Harvard and Georgia Tech to create a new diabetes treatment that involves transplanting insulin-producing pancreatic cells

Type 1 diabetes is estimated to affect around 1.8 million Americans. Although type 1 diabetes often develops in childhood or adolescence, it can occur in adulthood.

Despite active research, type 1 diabetes has no cure. Treatment methods include taking insulin, monitoring your diet, managing blood sugar levels, and exercising regularly. Scientists have also recently discovered a new treatment method that holds promise.

A group of researchers from the University of Missouri, Georgia Institute of Technology, and Harvard University has proved the successful use of a novel Type 1 diabetes treatment in a large animal model in a new study published in Science Advances on May 13th. Their method includes transferring insulin-producing pancreas cells, known as pancreatic islets, from a donor to a recipient without the need for long-term immunosuppressive medicines.

According to Haval Shirwan, a professor of child health and molecular microbiology and immunology at the MU School of Medicine and one of the studys primary authors, people with Type 1 diabetes immune system may malfunction, leading it to target itself.

The immune system is a tightly controlled defense mechanism that ensures the well-being of individuals in an environment full of infections, Shirwan said. Type 1 diabetes develops when the immune system misidentifies the insulin-producing cells in the pancreas as infections and destroys them. Normally, once a perceived danger or threat is eliminated, the immune systems command-and-control mechanism kicks in to eliminate any rogue cells. However, if this mechanism fails, diseases such as Type 1 diabetes can manifest.

Diabetes impairs the bodys ability to produce or utilize insulin, a hormone that aids in the regulation of blood sugar metabolism. People with Type 1 diabetes are unable to manage their blood sugar levels because they do not produce insulin. This lack of control may result in life-threatening problems including heart disease, kidney damage, and vision loss.

Shirwan and Esma Yolcu, a professor of child health and molecular microbiology and immunology at the MU School of Medicine, have spent the last two decades targeting an apoptosis mechanism that prevents rogue immune cells from causing diabetes or rejection of transplanted pancreatic islets by attaching a molecule called FasL to the islets surface.

A type of apoptosis occurs when a molecule called FasL interacts with another molecule called Fas on rogue immune cells, and it causes them to die, said Yolcu, one of the studys first authors. Therefore, our team pioneered a technology that enabled the production of a novel form of FasL and its presentation on transplanted pancreatic islet cells or microgels to prevent being rejected by rogue cells. Following insulin-producing pancreatic islet cell transplantation, rogue cells mobilize to the graft for destruction but are eliminated by FasL engaging Fas on their surface.

Haval Shirwan and Esma Yolcu work in their lab at the Roy Blunt NextGen Precision Health building. Credit: University of Missouri

One advantage of this new method is the opportunity to potentially forgo a lifetime of taking immunosuppressive drugs, which counteract the immune systems ability to seek and destroy a foreign object when introduced into the body, such as an organ, or in this case, cell, transplant.

The major problem with immunosuppressive drugs is that they are not specific, so they can have a lot of adverse effects, such as high instances of developing cancer, Shirwan said. So, using our technology, we found a way that we can modulate or train the immune system to accept, and not reject, these transplanted cells.

Their method utilizes technology included in a U.S. patent filed by the University of Louisville and Georgia Tech and has since been licensed by a commercial company with plans to pursue FDA approval for human testing. To develop the commercial product, the MU researchers collaborated with Andres Garca and the team at Georgia Tech to attach FasL to the surface of microgels with proof of efficacy in a small animal model. Then, they joined with Jim Markmann and Ji Lei from Harvard to assess the efficacy of the FasL-microgel technology in a large animal model, which is published in this study.

Haval Shirwan looks at a sample through a microscope in his lab at the Roy Blunt NextGen Precision Health building. Credit: University of Missouri

This study represents a significant milestone in the process of bench-to-bedside research, or how laboratory results are directly incorporated into use by patients in order to help treat different diseases and disorders, a hallmark of MUs most ambitious research initiative, the NextGen Precision Health initiative.

Highlighting the promise of personalized health care and the impact of large-scale interdisciplinary collaboration, the NextGen Precision Health initiative is bringing together innovators like Shirwan and Yolcu from across MU and the UM Systems three other research universities in pursuit of life-changing precision health advancements. Its a collaborative effort to leverage the research strengths of MU toward a better future for the health of Missourians and beyond. The Roy Blunt NextGen Precision Health building at MU anchors the overall initiative and expands collaboration between researchers, clinicians, and industry partners in the state-of-the-art research facility.

I think by being at the right institution with access to a great facility like the Roy Blunt NextGen Precision Health building, will allow us to build on our existing findings and take the necessary steps to further our research, and make the necessary improvements, faster, Yolcu said.

Haval Shirwan and Esma Yolcu. Credit: University of Missouri

Shirwan and Yolcu, who joined the faculty at MU in the spring of 2020, are part of the first group of researchers to begin working in the NextGen Precision Health building, and after working at MU for nearly two years they are now among the first researchers from NextGen to have a research paper accepted and published in a high-impact, peer-reviewed academic journal.

Reference: FasL microgels induce immune acceptance of islet allografts in nonhuman primates by Ji Lei, Mara M. Coronel, Esma S. Yolcu, Hongping Deng, Orlando Grimany-Nuno, Michael D. Hunckler, Vahap Ulker, Zhihong Yang, Kang M. Lee, Alexander Zhang, Hao Luo, Cole W. Peters, Zhongliang Zou, Tao Chen, Zhenjuan Wang, Colleen S. McCoy, Ivy A. Rosales, James F. Markmann, Haval Shirwan and Andrs J. Garca, 13 May 2022, Science Advances.DOI: 10.1126/sciadv.abm9881

Funding was provided by grants from the Juvenile Diabetes Research Foundation (2-SRA-2016-271-S-B) and the National Institutes of Health (U01 AI132817) as well as a Juvenile Diabetes Research Foundation Post-Doctoral Fellowship and a National Science Foundation Graduate Research Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

The studys authors would also like to acknowledge Jessica Weaver, Lisa Kojima, Haley Tector, Kevin Deng, Rudy Matheson, and Nikolaos Serifis for their technical contributions.

Potential conflicts of interest are also noted. Three of the studys authors, Garca, Shirwan, and Yolcu, are inventors on a U.S. patent application filed by the University of Louisville and the Georgia Tech Research Corporation (16/492441, filed Feb. 13, 2020). In addition, Garca and Shirwan are co-founders of iTolerance, and Garca, Shirwan, and Markmann serve on the scientific advisory board for iTolerance.

See the original post:
Harvard Scientists Have Developed a Revolutionary New Treatment for Diabetes - SciTechDaily

Upon receiving a diagnosis of type 1 diabetes (T1D), many people have the same reaction: But why me?

Some people have T1D that runs in their family, while others have no idea how or why they received a diagnosis. Often, to their frustration, those questions go unanswered.

But some people can seemingly link their T1D diagnosis to a previous virus they had endured directly before their onset of T1D.

This makes sense, as T1D is an autoimmune disease. This means your bodys own immune system mistakenly attacks its own insulin-producing beta cells. Although scientists dont know the exact causes or reasons why T1D develops, some researchers believe this haywire immune system reaction is the result of a virus triggering your bodys defense system to go into overdrive.

Viruses are now one main hypothesis of the cause of T1D. In particular, coxsackievirus is on the rise in those with newly diagnosed T1D. That has led some to wonder if theres a direct correlation between this virus, or any virus for that matter.

Read on for more about coxsackievirus, how it materializes in people, and what research has to say about its potential for causing T1D.

Coxsackievirus is a virus thats part of the enterovirus family, which lives in the human digestive tract. This enterovirus family also includes polioviruses, hand, foot, and mouth disease (HFMD), and hepatitis A virus.

This virus spreads easily from person to person, usually through human touch or on surfaces contaminated with feces. The virus can live for several days without a host, making it extremely easy to spread.

When theres a coxsackievirus outbreak, its most likely to affect babies and children younger than 5 years old, as its easily spreadable in places such as daycare centers, schools, and summer camps. Youre most contagious the first week that youre sick, and the best preventive mechanism is hand washing.

Usually, infection with this virus results in these mild flu-like symptoms initially:

Many people have no symptoms at all, and most people recover without treatment. But sometimes the virus can trigger more serious conditions or reactions, such as with HFMD, where a blister-like rash may appear on your hands or feet or in your mouth.

Theres no specific treatment for this virus, and antibiotics dont help with viral infections.

When a virus invades your body, your immune system produces antibodies to fight off that infection. T cells are in charge of developing antibodies as well as fighting off the virus.

But if the virus has some of the same antigens (or substances that cause your immune system to produce antibodies against them) as your bodys own pancreatic beta cells (in the case of T1D), the T cells sometimes start attacking your bodys own beta cells.

This miscommunication is common and results in autoimmune diseases like T1D. Once all the beta cells have been destroyed, T1D is developed and diagnosed. This is why people sometimes receive a diagnosis of T1D a few months after recovering from a bad virus.

But it can sometimes take more than a year for your bodys T cells to destroy the majority of your beta cells (sometimes people experience the honeymoon phase of diabetes, where their pancreas is still producing a minimal amount of insulin), but that original viral infection is hypothesized to be a trigger in the development of T1D.

Not every virus can trigger this reaction ending in T1D. The virus must have antigens that are similar enough to the antigens in pancreatic beta cells. Those viruses include:

Theres mounting evidence that the coronavirus disease 19 (severe acute respiratory syndrome coronavirus 2) pandemic is causing a tidal wave of new T1D diagnoses to be received by both children and adults. But the full repercussions of the pandemic are yet to be seen.

A 2018 study showed that kids exposed to enteroviruses are more likely to develop T1D.

The Environmental Determinants of Diabetes in the Young study found, through nearly 8,000 stool samples of children in the United States and Europe, an association between an exposure and infection with coxsackievirus. This study followed participants for 30 days or longer and focused on the development of an autoimmune reaction that can lead to a T1D diagnosis.

In a Finland-based study, researchers tested more than 1,600 stool samples from 129 children who had recently developed T1D. They also tested 282 children without diabetes for enterovirus RNA, a marker of previous exposure to infection.

Researchers also found 60 percent of the control group showed signs of prior infection (without diabetes), compared with 75 percent of the group with T1D.

They also found that children who developed T1D were exposed to the virus more than a year before their diabetes was diagnosed. Taking this lag time of viral infection to T1D diagnosis into account, the researchers believed that children with diabetes are exposed to three times more enteroviruses than children without diabetes.

Viral infections arent the only hypothesized cause of T1D, but research is homing in on viruses as a common trigger. Studies have shown that even if pregnant people are exposed to enteroviruses, such as coxsackievirus, theyre more likely to give birth to children who eventually develop T1D.

Researchers arent exactly sure what the precise cause of T1D is, and the virus hypothesis is just one theory. Many people believe that T1D is caused by a mix of genetic and environmental factors and that the disease may just be finally triggered by catching a virus such as coxsackievirus or another enterovirus.

While preventing viral spread is always important, even if all enteroviruses were prevented, T1D wouldnt be prevented in everyone, but it would probably make a big difference.

Researchers are hopeful with new trials showing vaccines against enteroviruses could potentially prevent many new diagnoses of T1D, but they wont prevent all people from receiving diagnoses of course.

While theres no vaccine to prevent T1D, Dr. Denise Faustman, Director of the Massachusetts General Hospital Immunobiology Laboratory, is working on that research front. Her work focuses on the bacillus Calmette-Gurin (BCG) vaccine, traditionally used to prevent tuberculosis, and how it can help people with T1D. Specifically, this century-old BCG vaccine may boost a substance called tumor necrosis factor, which eliminates T cells and helps develop more beneficial cells called regulatory T cells.

If you have diabetes, this could help improve your blood sugar and A1C levels while lowering your insulin requirements even years after your initial vaccination. That research is expected to continue for at least several more years beyond 2022.

The exact causes of T1D arent known. But research shows enteroviruses, and in particular coxsackievirus, may play a part in the development of this autoimmune condition. Most researchers believe it to be a mix of both environmental and genetic factors, with perhaps a viral infection trigger. Research remains ongoing, and the development of a coxsackievirus vaccine could go a long way in preventing people worldwide from receiving diagnoses of T1D in the future.

Read this article:
Do Viruses and Coxsackievirus Cause Type 1 Diabetes? - Healthline

While managing diabetes can be challenging, you can still do the things you enjoy in life. (Getty Images)

This diabetes week, and every week, it's important that just because diabetes is a hidden condition, it doesn't get ignored.

One in 14 of us live with the condition, while even more care for a loved one who does, according to Diabetes UK.

So, whether you might suspect you have diabetes, support someone else with it, are recently diagnosed, or just want to learn more about the condition, here are the basics of what there is to know.

Read more: Kate Moss' daughter Lila proudly sports blood glucose monitor in Fendace campaign

If you're diagnosed with diabetes, a medical professional will explain all you need to know about managing it. (Getty Images)

Diabetes is a lifelong condition that causes a person's blood glucose levels (also called blood sugar) to become too high, according to the NHS. There are two main types, Type 1 and Type 2, though some can also get Gestational diabetes.

Pre-diabetes is when people have blood glucose levels above the normal range, but are not high enough to be diagnosed with the condition itself. But it's important to keep in mind that if your levels are higher than most, your risk of developing full-scale diabetes is increased.

Getting diabetes diagnosed early is key to prevent it from getting progressively worse, which can happen if left untreated.

The finger-prick test has long been used to manage diabetes, though there are now more advanced methods. (Getty Images)

Type 1 diabetes is where the body's immune system attacks and destroys the cells that produce insulin. You need to take insulin every day to keep your blood glucose levels under control. Type 1 is not linked with age, being overweight or lifestyle factors, whereas Type 2 is.

The NHS website says you should see a GP if you have symptoms of type 1, which include:

feeling very thirsty

peeing more than usual, particularly at night

feeling very tired

losing weight without trying

thrush that keeps coming back

blurred vision

cuts and grazes that are not healing

fruity-smelling breath

Type 1 signs and symptoms can come on quickly, particularly in children.

To get tested, your GP will do a urine test and might also check your blood glucose level. If they suspect you have diabetes, you'll be advised to go to hospital immediately for further assessments, where you will stay until you get results (usually the same day).

Story continues

If you are diagnosed, then a specialist diabetes nurse will explain everything you need to know about the condition, including how to manage it, test your own blood glucose and how to inject insulin.

Finger-prick tests have long been used to manage diabetes, though you can now check your glucose levels at any time with a continuous glucose monitor (CGM) or flash monitor.

This involves using a sensor, a small device you attach to your arm or tummy that senses how much glucose is in the 'interstitial' fluid under your skin, and a reader or receiver, which shows the results (you can also read them on your smartphone). Some types have optional alarms to alert you if your levels go too low or high.

Read more: What types of dementia are there? Signs and symptoms to see your GP about

While interstitial fluid readings have made many people living with diabetes' lives much easier, it's important to remember they're a few minutes behind your blood glucose levels. This means you'll still need to do finger-prick checks every now and then, particularly when you drive or have a hypoglycaemia (when your blood glucose level is too low), as this tells you what your level is at that moment.

Although being diagnosed with and managing diabetes can be difficult at times, you can still do the things you enjoy. This useful NHS guide on being newly diagnosed provides information to help, including how to recognise and treat a hypo, useful websites, online courses and more.

Do you have the symptoms of diabetes? (Getty Images)

Type 2 diabetes is where the body does not produce enough insulin, or the body's cells do not react to insulin. It is far more common than type 1, with around 90% of all adults in the UK with diabetes living with it.

It can be linked to being overweight or inactive, or having a family history of type 2 diabetes. You're also more at risk of this type of diabetes if you're over 40 (or 25 for south Asian people), have a close relative with diabetes, are overweight or obese, are of Asian, African-Caribbean or black African heritage.

Many people can have type 2 diabetes without realising, because symptoms don't always make you feel unwell.

The NHS website says you should see a GP if you have symptoms of type 2 (similar to type 1), which include:

peeing more than usual, particularly at night

feeling thirsty all the time

feeling very tired

losing weight without trying to

itching around your penis or vagina, or repeatedly getting thrush

cuts or wounds taking longer to heal

blurred vision

You should also see a GP if you're worried you may have a higher risk of getting type 2. You check your risk here.

Some people find checking blood glucose levels with a continuous glucose monitor (CGM) or flash monitor easier. (Getty Images)

Gestational diabetes can also occur during pregnancy, when some women have such high levels of blood glucose that their body is unable to produce enough insulin to absorb it all.

While it can happen at any stage of pregnancy, it is more common in the second or third trimester. It usually disappears after giving birth.

That said, it can cause problems for you and your baby during pregnancy and after birth, but the risks can be reduced if the condition is detected early and well managed.

Read more: How to stay safe in hot weather: Top tips to avoid heatstroke this summer

With the causes of Type 1 and Type 2 different, a doctor will explain how management differs. (Getty Images)

Elaborating on the above, the amount of sugar in the blood is controlled by a hormone called insulin, which is produced by the pancreas (a gland behind the stomach), the NHS explains.

Normally, when food is digested and enters your bloodstream, insulin moves glucose out of the blood and into cells, where it's broken down to produce energy.

However, if you have diabetes, your body is unable to break down glucose into energy because there's either not enough insulin to move it, or the insulin produced doesn't work properly.

While there are no lifestyle changes you can make to lower your risk of of type 1 diabetes, you can help manage type 2 diabetes through healthy eating, regular exercise and achieving a healthy body weight.

There's nothing you can't eat if you have type 2 diabetes, but the NHS suggests limiting certain foods. You should eat a wide range of food (fruit, veg and some starchy foods like pasta), keep sugar, fat and salt to a minimum, and make sure you eat breakfast, lunch and dinner every day do not skip meals.

If you need to change your diet, it might be easier to make small changes every week, it adds.

Altering your lifestyle in small ways can go a long way to reduce your risk of type 2 diabetes. (Getty Images)

Diet, exercise and a healthy lifestyle can also help to reduce the likelihood of getting type 2 diabetes, with more than 13.6 million people in the UK at an increased risk.

"Fortunately even in people with a strong family history of diabetes making positive lifestyle choices can help avoid diabetes altogether," says Dr Sundhya Raman, Medical Doctor and Lifestyle Medicine Physician, Plant Based Health Professionals.

In terms of diet, Ruman says we should try to avoid "processed foods, sugar-sweetened foods and drinks, saturated fats (found in animal source foods and tropical oils), and red and processed meats".

On exercise, she explains it is never too late to start, and build up gradually. "Most people think they need to be quite fit before they get a benefit from exercising, but in fact going from doing nothing to doing something is when the biggest gains are achieved."

It seems sleep is very important too. "We should all be aiming for 7-8 hours of sleep a night, and people who chronically sleep less than this amount raise their risk of diabetes by about 30%," she says.

"When we dont get enough sleep we also have dysregulated levels of our hunger and satiety hormones so are more likely to eat more, particularly foods that are not good for us and make us put on weight, so sleep should also be a priority."

Of all lifestyle factors, Raman says poor diet is the biggest risk. "In studies, the dietary group who have the lowest rates of diabetes are whole-food plant based. They are also the group that tend to have the lowest BMI compared with any other dietary group such as pescatarians or omnivores, and we know that a high BMI is one of the most significant risk factors [for having diabetes].

Some believe food is medicine when it comes to reducing your risk of diabetes, or even reversing it. (Getty Images)

Plant-based diets can reduce the risk of type 2 diabetes by up to 60%, according to Plant Based Health Professionals. But how does this work?

Soluble fibre, she explains helps us to feel full and maintain a healthy weight, release the carbohydrate from our food into our bloodstream slowly, and is the superfood for bugs that live in our colon, of which a healthy balance of can lower the risk of diabetes.

"Plant foods are also full of antioxidants that help reduce the damage that happens to our cells from everyday activities, as well as some of the more damaging things we do such as eating the wrong kinds of foods or sitting for prolonged periods," Ruman adds. "We also know that some of the compounds in plant foods switch on genes that optimise our metabolism.

She also says wholegrains are the food type that have been shown in studies to be particularly important in reducing diabetes and cardiovascular risk. However, in the UK we don't have specific guidelines on how many portions to eat, or any legislation on what can be termed a wholegrain, so people can eat processed foods with few wholegrains, thinking they are improving their health, or think they're bad for people with diabetes, as are often grouped under carbs.

Read more: Earth Day 2022: 7 ways to reduce your carbon 'foodprint' to save the planet

"I would recommend 3 portions of wholegrains per day, ideally as unprocessed as possible." She also reccomends a variety of fruit and vegetables, as well as variety in your nuts, seeds, wholegrains, lentils, legumes, herbs and spices, while prioritising plant sources of proteins over those from animal sources.

In some cases, plant-based are also effective at reversing Type 2 diabetes, effective at reversing insulin resistance, which is thought to happen fat gets stored in our muscle and liver, and damages cells."One of the ways in which a whole-food plant-based diet is incredibly beneficial is that people tend to lose weight when they follow this dietary pattern, and we know that weight loss can reverse diabetes."

Make sure you consult a doctor before making any big dietary changes.

For more information, visit the NHS' website on diabetes, or seek support from Diabetes UK on 0345123 2399.

Watch: Diabetes drug leads to significant weight loss in those with obesity, study finds

The rest is here:
Diabetes Week: Types 1 and 2 symptoms, causes and prevention - Yahoo Entertainment

MadameNoire Featured Video

Source: Adene Sanchez / Getty

Great sex, anecdotally, is uninhibited and free of worry. Its a time to put aside the usual responsibilities that plague you and just enjoy the moment. But diabetes and sex have a slightly complicated relationship. For people with type 1 diabetes, fully detaching from responsibilities isnt an option in fact, it can be dangerous. Its no surprise then that a study conducted by Oxford University professors found that 62 percent of people with diabetes say their condition has negatively impacted their relationships with their partners.

Having to think about your type 1 diabetes during intimacy can be agitating and even disheartening. But its important to remember that many adults have to do some planning before sex. Some men have to take pills for erectile dysfunction. Tons of women need lubricant due to a hormonal imbalance. And lets not forget about all of the people who need a lumbar support pillow for missionary. Everyone deserves to enjoy sex. Heres what you need to know about having safe and enjoyable sex, when you have type 1 diabetes.

Source: Andriy Onufriyenko / Getty

There are several reasons that those with type 1 diabetes cant explore the Kama Sutra without some planning. First off, a lot of sex depending on how you go about it counts as a workout. It gets your blood pumping, it gets you sweating and, like any exercise, it impacts blood sugar levels. While people who dont have diabetes can handle these blood sugar fluctuations fairly well, people with diabetes need to be careful.

Next, theres the added factor of booze. Its common for people to enjoy a drink (or a few) before having sex. Alcohol helps loosen those inhibitions and make you feel relaxed. But, if you drink too much or dont stick to diabetic-friendly cocktails, your blood sugar levels can go on a roller coaster.

The ways sex plays on blood sugar levels dont stop there. Even if you stay sober for sex, the mere excitement of being with a partner can impact blood sugar levels. So, while its frustrating, the fact that sex affects blood sugar levels cannot be ignored.

Source: kali9 / Getty

If you know that your night will likely end in sex, take steps to put your blood sugar levels in a healthy range by the time intimacy occurs. This means being careful about what you eat, using insulin when necessary and even monitoring other physical activity throughout the day. If your sessions in the sack are particularly active, then you might need to skip your afternoon workout. You dont want to put yourself at risk of low blood sugar mid-coitus due to over-exertion.

Source: NurPhoto / Getty

Even if you eat right and monitor your blood sugar levels, things can still go awry after a few rounds with your partner. Be sure to keep snacks on the nightstand so you can reach for them if you feel your blood sugar levels dropping. Better yet, incorporate sexy foods like strawberries or chocolate sauce (sugar-free if necessary) into sex so it doesnt feel like snack time is putting a pause on the fun.

Source: FG Trade / Getty

Sex is always better when you can communicate with your partner. That is true about every topic, from what positions work for you to managing your blood sugar levels. Notify your partner in advance that sex can impact your blood sugar, and that you might need to pause during the activities to have a snack or take insulin. Additionally, if you can tell tonight is just not a good night to do the deed, speak up. Pushing yourself through sex when your blood sugar levels are off can be dangerous.

Source: Andriy Onufriyenko / Getty

If you wear an insulin pump or a blood glucose monitor, you might be tempted to remove this during sex. Some diabetics struggle to feel sexy when wearing these devices (and nothing else) in front of a partner. First off, theres no shame in wearing a device that keeps you alive and enables you to live the way that you enjoy. However, there are some practicalities to consider, like the fact that these devices can get tangled or fall off during sex.

If you want to remove your device during sex, make sure to get your blood sugar levels in a healthy range right before the activities. And then put the device back on immediately after sex. If your blood sugar levels arent stable enough for device removal, get creative and choose positions that let you keep the device on. Again, communication is key here.

Source: Andreas Stamm / Getty

It is important to know that type 1 diabetes can impact sexual function in many ways. For women, high blood sugar can lead to vaginal dryness, according to the Journal of Natural Science, Biology and Medicine. For men, blood sugar issues can cause erectile dysfunction. And people of all genders can experience mood swings and a low libido in connection to type 1 diabetes.

While there are practical fixes for vaginal dryness like finding a lubricant you love the other symptoms can be more complicated to treat. If you are struggling with any of these issues, first off, know that its common for people with type 1 diabetes and is nothing to be embarrassed about. Then talk to your doctor about the best way to treat the problem.

Having type 1 diabetes doesnt have to mean the end of a fun, playful and even erotic sex life. It simply means you have to do a little extra planning. But when you have a partner with whom you can communicate openly, that planning wont feel like a burden. And when you know your body will be safe and taken care of, then you can let go and be in the moment.

RELATED CONTENT:7 Things Doctors Wish Black Women Knew About Diabetes

Go here to see the original:
Diabetes And Sex: Have Safe Sex While Managing Diabetes - MadameNoire

Wilmington, Delaware, United States: According to Transparency Market Researchs latest report on the global diabetes devices market for the historical period 20172018 and forecast period 20192027, increase in prevalence of diabetes, and increase in adoption of insulin pumps among type 1 diabetes patients are projected to drive the global diabetes devices market during the forecast period.

According to the report, the global diabetes devices market was valued at US$ 41.8 Bn in 2018 and is anticipated to expand at a CAGR of 6.4% from 2019 to 2027.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14

Increase in Prevalence of Diabetes Expected to Drive Global Diabetes Devices Market: Key Drivers

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14

Increase in Adoption of Insulin Pump among Type 1 Diabetes Patients Boost Market Growth

Request for Analysis of COVID19 Impact on Diabetes Devices Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=14

Threat of Alternative Therapies for Diabetes to Hamper Market

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=14

Global Diabetes Devices Market: Competitive Landscape

This report profiles major players in the global diabetes devices market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global diabetes devices market is highly fragmented, with the presence of a number of international as well as regional players

Leading players operating in the global diabetes devices market are

More Trending Reports by Transparency Market Research

Audiological Devices Market: https://www.transparencymarketresearch.com/audiological-devices-market.html

Eye Care Surgical Devices Market: https://www.transparencymarketresearch.com/eye-care-surgical-devices-market.html

Breast Reconstruction Market: https://www.transparencymarketresearch.com/breast-reconstruction-market.html

Radiation Therapy Market: https://www.transparencymarketresearch.com/radiation-therapy-market.html

Thyroid Function Test Market: https://www.transparencymarketresearch.com/thyroid-functioning-tests-market.html

Roadside Drug Testing Devices Market: https://www.transparencymarketresearch.com/us-roadside-drug-testing-devices-market.html

Smart Fertility Tracker Market: https://www.transparencymarketresearch.com/smart-fertility-tracker-market.html

Radiation Therapy Market: https://www.transparencymarketresearch.com/radiation-therapy-market.html

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

The rest is here:
Diabetes Devices Market to Expand at the CAGR of 6.4% from 2019 to 2027, Increase in Prevalence of Diabetes Expected to Drive Global Market - BioSpace

If you live with diabetes, you may be aware that having the condition and its complications may put you at greater risk of developing anemia. But how are the two conditions related and what does this mean for you?

This article will investigate the relationship between diabetes and anemia, and what you should know if you have diabetes-related complications impacting your life.

According to the National Heart, Lung, and Blood Institute, Anemia is a condition in which the blood doesnt have enough healthy red blood cells to function properly. This leads to reduced oxygen flow to the bodys organs.

There are more than 3 million cases of anemia diagnosed in the United States every year, making this a very common condition.

You may experience the following symptoms:

Its important to note that some anemia symptoms are similar to symptoms of high blood sugar, including dizziness, lightheadedness, extreme fatigue, rapid heart rate, and headache.

Check your blood sugar often to make sure youre not confusing high blood sugar for suspected anemia. If your symptoms continue for a few days or weeks without high blood sugar numbers or ketones, call a healthcare professional to get checked for anemia.

Diabetes doesnt cause anemia and anemia doesnt cause diabetes. The two conditions are related, though.

Up to 25 percent of Americans with type 2 diabetes also have anemia. So its relatively common for people with diabetes, and especially diabetes-related complications, to also develop anemia.

However, if you have one condition or the other, you wont automatically develop the other condition.

As seen in this 2004 study, Anemia is a common complication of people with diabetes who develop chronic kidney disease because damaged or failing kidneys dont produce a hormone called erythropoietin (EPO), which signals to the bone marrow that the body needs more red blood cells to function.

Early stages of kidney disease (nephropathy) may be asymptomatic, but if youre diagnosed with anemia and you have diabetes, it might be a sign that your kidneys arent working properly.

People with diabetes are also more likely to have inflamed blood vessels. This prevents the bone marrow from even receiving the EPO signal to create more red blood cells to begin with. That makes anemia a more likely result.

Additionally, if you have existing anemia and are then diagnosed with diabetes, it may make you more likely to develop diabetes-related complications, such as retinopathy and neuropathy (eye and nerve damage).

A lack of healthy red blood cells can additionally worsen kidney, heart, and artery health, systems that are already taxed with a life lived with diabetes.

Certain diabetes medications can decrease your levels of the protein hemoglobin, which is needed to carry oxygen through the blood. These diabetes medications can increase your risk of developing anemia:

Since blood loss is also a significant contributor to the development of anemia, if you have diabetes and are on kidney dialysis, you may want to talk with your healthcare team about your increased risk of anemia as well.

Anemia can affect blood sugar levels in several ways.

One 2010 study found that anemia produced false high blood sugar levels on glucose meters, leading to dangerous hypoglycemia events after people overtreat that false high blood sugar.

As shown in a 2014 study, theres a direct link between anemia caused by iron deficiency and higher amounts of glucose in the blood. A 2017 review of several studies found that in people both with and without diabetes, iron-deficiency anemia was correlated with increased A1C numbers.

This resulted from more glucose molecules sticking to fewer red blood cells. After iron-replacement therapy, HbA1c levels in the studies participants decreased.

If you receive an anemia diagnosis and you live with diabetes, there are many excellent treatment options.

Treatment will depend on the underlying cause of the condition, but may include supplementation with iron and/or vitamin B.

If your anemia is caused by blood loss, a blood transfusion may be necessary. If your bodys blood production is reduced, medications to improve blood formation may be prescribed.

Diabetes and anemia are closely related, though neither directly causes the other condition.

Diabetes-related complications such as kidney disease or failure and inflamed blood vessels may contribute to anemia. Certain diabetes medications can also increase the likelihood of developing anemia. Anemia may also make diabetes management more challenging, with higher A1C results, false high blood sugars, and a potential risk of worsening organ health leading to future diabetes complications.

Still, anemia is very treatable with supplementation, dietary or medication changes.

Visit link:
Anemia and Diabetes: What You Should Know - Healthline

Patient education is a component of prevention of progression of kidney disease. Paul Flynn and colleagues at SUNY Downstate Health Science University, Brooklyn, New York, interviewed patients with end-stage kidney disease (ESKD) secondary to diabetic kidney disease to determine their knowledge of their disease and how it relates to chronic kidney disease (CKD).

Results of the interviews were reported during a poster session at the NKF 2022 Spring Clinical Meetings. The poster was titled Knowledge Gaps Regarding Chronic Kidney Disease and Diabetes in a Population of Inner-City Dialysis Patients.

The survey was administered to 15 randomly selected dialysis patients with diabetes. The survey included questions about patient knowledge about diabetes and kidney disease at the time of diagnosis. The researchers also collected demographic information.

Mean age of the respondents was 64.3 years, 53% (n=8) were male, 47% (n=7) had less than a college education, 89% (n=8/9) made less than $40,000 per year. Mean time with diabetes was 29.0 years. Eight of 13 patients saw an endocrinologist, and four reported most recent hemoglobin A1c (HbA1c) >10%. Twelve of 13 respondents reported they had no knowledge of what CKD was and 10 of 13 did not know at the time of their diabetes diagnosis that diabetes could cause kidney disease.

There was no correlation between knowledge and age, education, length of time with diabetes, income, or sex. Patients who were older were lesse likely to see an endocrinologist (r=0.64; P=.019), checked their glucose less frequently (r=0.71; P=.006), and did not check after eating (r=0.62; P=.023). Thirteen of 14 patients said they did know what HbA1c was, 11 of 14 knew that insulin decreases blood glucose levels, 12 of 14 knew that a person with type 2 diabetes had increased blood glucose, and ten of 14 patients knew that HbA1c should be checked every 3 months. Six of 13 patients did not know what a nephrologist is and nine of 13 did not know how kidney function is measured.

In summary, the authors said, In our population of inner-city dialysis patients with diabetes mellitus: (1) The majority were knowledgeable about diabetes, although older patients were less likely to see an endocrinologist and check their blood sugar frequently or after eating. (2) The majority of patients had no knowledge of kidney disease and did not know that diabetes could cause kidney disease at the time of their diagnosis. (3) Almost half of patients currently did not know what a nephrologist was and did not know how kidney function is measured. (4) An early education program for our underserved population regarding the relationship between kidney disease and diabetes should be designed in the hopes of delaying progression to ESKD.

Source: Flynn P, Sherman B, Wei L, et al. Knowledge gaps regarding chronic kidney disease and diabetes in a population of inner-city dialysis patients. Abstract of a poster presented at the National Kidney Foundation 2022 Spring Clinical Meetings (Abstract 273), Boston, Massachusetts, April 6-10, 2022.

Here is the original post:
Patient Knowledge of Diabetes and CKD in an Inner-City Population - DocWire News

BASEL, Switzerland, June 16, 2022 /PRNewswire/ --Ascensia Diabetes Care, a global diabetes care company,maker of CONTOURblood glucose monitoring (BGM) system portfolio and distributor of Eversense Continuous Glucose Monitoring (CGM) Systems, announces that its partner Senseonics Holdings, Inc. has received CE Mark approval for the Eversense E3 Continuous Glucose Monitoring (CGM) System, clearing the way for its use in European Union (EU) member countries. Ascensia plans to make the next-generation system, which can be used for up to 6 months, available to patients in certain European markets from the third quarter of 2022.

The fully implantable, long-term Eversense E3 CGM System has been designed to deliver key improvements on the currently available Eversense XL CGM System, whilst building on the unique benefits that European users already experience. The next-generation system offers exceptional accuracy and long-term sensor wear, alongside reduced frequency of calibration and significantly enhanced sensor survivability. Unlike the XL System, the new E3 System has also been approved for non-adjunctive use, meaning that it can inform insulin treatment decisions without confirmation of glucose levels from fingerstick testing. Both Eversense XL and Eversense E3 are approved for use up to 6 months, making them the longest lasting CGM sensors available. This gives people with diabetes freedom from the burdens associated with other available CGM systems, such as weekly or bi-weekly self-insertions.

Eversense E3 is already available in the U.S. following FDA approval and launch earlier this year. Following the CE Mark approval in Europe the Eversense E3 System will be distributed in Germany, Italy, Spain (including Andorra), the Netherlands, Poland, Switzerland, Norway and Sweden.

Robert Schumm, President at Ascensia Diabetes Care, said, "This approval is an exciting milestone for us as we look forward to bringing Eversense E3 to people with diabetes across Europe. From this next-generation system you can expect the excellent features and benefits that European users currently experience with Eversense XL, but with design improvements that address requests we repeatedly hear from patients and healthcare providers. Our role is to make sure that as many people have access to this innovative product as possible, and efforts are already under way to launch this system in certain European countries in the coming months."

Developed by Senseonics and brought to people with diabetes by Ascensia, the newly approved Eversense E3 CGM System offers patients:

"The features and benefits of this improved system offer people with diabetes unparalleled flexibility, convenience and accuracy," said Elaine Anderson, Head of Eversense CGM Business Unit at Ascensia Diabetes Care. "Choice is key in managing diabetes and we are proud to work alongside our partner Senseonics to bring an outstanding and unique CGM option to patients and healthcare providers across Europe and in the U.S."

People in these markets who are interested in getting started with Eversense XL now can visit http://www.ascensia.com/eversense for more information, and will be among the first to know when Eversense E3 is commercially available.

* There is no glucose data generated when the transmitter is removed.

1 Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182

SOURCE Ascensia Diabetes Care

See the article here:
ASCENSIA DIABETES CARE ANNOUNCES EUROPEAN APPROVAL OF THE NEXT-GENERATION EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM - PR Newswire

What should diabetes health care professionals consider when treating patients who have sickle cell trait or disease?

World Sickle Cell Day is observed annually on June 19th to raise awareness of sickle cell disease, a group of inherited red blood cell disorders that affect more than 100,000 people in the United States and 20 million people worldwide. For people with sickle cell disease, red blood cells are crescent or sickle shaped and do not bend or move easily, which can block blood flow to the rest of the body and cause repeated infections and episodes of pain.

Hemoglobinopathies (also called hemoglobin variants) are inherited red blood cell conditions that affect hemoglobin, the protein that carries oxygen through the body. One of the most common hemoglobinopathies is hemoglobin S, the sickle cell gene. In a severe form of sickle cell disease, sickle cell anemia, a patient inherits two genes for hemoglobin S.

Patients can also inherit one sickle cell gene and have sickle cell trait, often with no signs or symptoms. This means that many patients are unaware they have sickle cell trait. It is also worth noting that certain populations are more likely to inherit sickle cell traitabout 1 in 13 African Americans and about 1 in 100 Hispanics/Latinos have sickle cell trait.

Sickle Cell Hemoglobinopathies and the A1C Test

For patients who have the sickle cell gene or other hemoglobinopathies, some A1C testing methods for blood glucose may produce unreliable results. An A1C test with falsely high outcomes could lead to the prescription of more aggressive treatments, resulting in increased episodes of hypoglycemia. Conversely, falsely low outcomes could lead to the undertreatment of diabetes.

Laboratories use many different assay methods to measure A1C. Health care professionals should suspect the presence of a hemoglobinopathy when

For more information about hemoglobinopathies and alternative tests to measure blood glucose levels, view NIDDKs health information on Sickle Cell Trait & Other Hemoglobinopathies & Diabetes.

And to learn more about NIDDK Director Dr. Griffin P. Rodgers career researching blood conditions, including sickle cell, watch the videos below.

Link:
Understanding the Link between Diabetes Care and Sickle Cell Disease | NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases...

The number of children being treated at paediatric diabetes units (PDUs) in England and Wales has increased by more than 50% amid a perfect storm of rising obesity levels and the cost of living crisis, health leaders have said.

Diabetes UK said alarming obesity levels among children had led to a concerning climb in the number diagnosed with type 2 diabetes, and predicted that the cost of living crisis could lead to further problems in the years to come.

Data from NHS Digital shows that almost one in seven children start primary school obese a rise of almost 50% in just a year. More than a quarter are obese by the time they finish primary school.

Sign up to First Edition, our free daily newsletter every weekday morning at 7am BST

The high levels of obesity combined with the squeeze on personal finances are creating a perfect storm which risks irreversible harm to the health of young people, Diabetes UK said. It accused the government of letting our children down as it called for concerted action to tackle obesity.

It comes after the governments decision to delay measures to reduce unhealthy eating, weakening its anti-obesity strategy by postponing for a year a ban on buy one, get one free deals for foods high in fat, salt and sugar.

Demand for care for children with type 2 diabetes at paediatric diabetes units across England and Wales has increased by more than 50% in the last five years, according to the Diabetes UK analysis. A total of 973 children with type 2 diabetes were treated in PDUs in 2020-21, up from 621 in 2015-16.

PDUs employ a team of specialists to care for children with type 2 diabetes that can include consultants, nurses and dieticians. The team usually work in a hospital setting, where a child may attend appointments as an outpatient rather than being seen at their GPs surgery. Previous statistics have shown that in England alone, about 1,600 children have been diagnosed with type 2 diabetes.

Diabetes UK said children in the most deprived parts of England and Wales were disproportionately affected by the disease, with four in 10 children and young people with type 2 diabetes living in the poorest areas, compared with only one in 19 from the richest. This is similar to data for childhood obesity prevalence, it said.

The charity said that in light of the additional burden of the cost of living crisis, the poorest children would bear the brunt for decades to come.

Chris Askew, the chief executive of Diabetes UK, said: We are very concerned that this spike in childhood obesity will translate into an even greater increase in children with type 2 diabetes in the coming years, a crisis fuelled by longstanding health inequalities and made worse still by impacts of the cost of living crisis.

Government needs to entirely rethink its commitment to child health. This must start with urgently reversing the decision to backtrack on their obesity strategy commitments and go further still, with bold steps to address childhood obesity and poorer outcomes for children living in poverty in the forthcoming health disparities white paper.

The UK government is letting our children down. With soaring numbers of children now living with obesity, and numbers diagnosed with type 2 diabetes on a very concerning climb, we are facing a perfect storm, which risks irreversible harm to the health of young people.

Continued here:
Child type 2 diabetes referrals in England and Wales jump 50% amid obesity crisis - The Guardian